DICE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin lymphoma

VernacularTitle:DICE方案治疗复发或耐药侵袭性淋巴瘤的临床研究
Author: Lin TAN ; Yun ZENG ; Yu XIE ; Jian YANG
Publication Type:Journal Article
Keywords: Lymphoma,non-Hodgkin's; Drug therapy,combination; Antineoplastic combined chemotherapy protocols
From: Journal of Leukemia & Lymphoma 2009;18(1):32-34
CountryChina
Language:Chinese
Abstract: Objective To evaluate the efficacy of DICE regimen on relapsed or refractory NHL,and observe its toxicitv.Methods Records of 50 patients with relapsed or refractory invasive NHL were treated with DICE regimen.All patients had received at least 1 type of chemotherapy regimen with a median of 6 cycles.The patients received a median of 4 cycles of DICE regimen.Resuits The treatment outcome and adverse events of all patients were analyzed.The overall response rate was 48.0%.with a complete response (CR)rate of 16.0%.The response rates were 53.8%in the 26 patients with B-cell lymphoma and 29.2% in the 24 patients with T-cell lymphoma.The 1-and 2-year survival rates were 34.0%and 8.0%,respectively.The major adverse event was myelosuppression:the prevalence of grad eⅢ-Ⅳ neutropenia Was 38.0%,and that of grade Ⅲ-Ⅳ was 14.0%.One patient suffered grade Ⅲ liver toxicity.Conclusion DICE regimen Was effective for patients with relapsed or refractory invasive NHL, and its toxicity is well tolerated,but the response term is relatively short.Further clinical study on the application of DICE regimen iS needed.